-
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
09 Jul 2025 20:47 GMT
… real-world treatment impact.
Daiichi Sankyo has shared final long … president, US medical affairs, Daiichi Sankyo, added: “The final results … the long-term benefit of Turalio. Daiichi Sankyo is proud to … 3 Trial. News release. Daiichi Sankyo. July 9, 2025. …
-
Pexidartinib Shows Long-Term Safety and Efficacy in Symptomatic TGCT
09 Jul 2025 20:40 GMT
… (Turalio) produced sustain clinical benefit among patients with symptomatic tenosynovial … Affairs at Daiichi Sankyo, added in the news release.1 “Daiichi Sankyo is proud … identify appropriate patients who may benefit from this treatment.”
References
…
-
AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
26 Jun 2025 07:23 GMT
… verification and description of clinical benefit in a confirmatory trial.
… commercialised by AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating Datroway … -directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology …
-
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC
25 Jun 2025 03:46 GMT
… verification and description of clinical benefit in a confirmatory trial.
… commercialised by AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating Datroway … verification and description of clinical benefit in a confirmatory trial. …
-
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For Type Of Lung Cancer
24 Jun 2025 11:09 GMT
… metastatic EGFR-mutated NSCLC indication. Daiichi Sankyo recognizes Datroway’s sales in … verification and description of clinical benefit in a confirmatory trial.
The … and commercialized by AstraZeneca and Daiichi Sankyo.
Dave Fredrickson, Executive Vice …
-
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
24 Jun 2025 10:15 GMT
… FDA) has approved AstraZeneca and Daiichi Sankyo’s Datroway (Datopotamab deruxtecan) … confirmation and detailed clinical benefit from a confirmatory study. … commercialised by both AstraZeneca and Daiichi Sankyo.
AstraZeneca oncology haematology business …
-
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer
24 Jun 2025 09:45 GMT
… verification and description of clinical benefit in a confirmatory trial.
The … breast cancer, was discovered by Daiichi Sankyo and is being jointly developed … and commercialised by AstraZeneca and Daiichi Sankyo.
Dave Fredrickson, executive vice president …
-
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
04 Jun 2025 22:13 GMT
… approval in January, AstraZeneca and Daiichi Sankyo have narrowed their development plans … certain patient populations might differentially benefit as we explore the path … may require Okuzawa to navigate Daiichi Sankyo through broader economic challenges, too …
-
AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab to treat HER2-positive metastatic breast cancer
03 Jun 2025 08:43 GMT
… verification and description of clinical benefit in a confirmatory trial.
Enhertu … clinical trial can demonstrate clinical benefit in this population.
Enhertu ( … Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible …
-
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab
02 Jun 2025 20:33 GMT
… in oncology trials.
AstraZeneca and Daiichi Sankyo have shared positive data from … (ASCO) Annual Meeting.
Robust PFS benefit observed across multiple patient subgroups … months for THP. The PFS benefit for Enhertu and pertuzumab was …
About
© 1995-2025